More from these Authors

• Case | HBS Case Collection | 2013

  Cummins, Inc.: Building a Home Community for a Global Company

  Joseph L. Bower and Michael Norris

  In 2010, Tom Linebarger, president and COO of Cummins, Inc., the Columbus, Indiana-based manufacturer of diesel engines, has to decide where to locate the company's new manufacturing line for high horsepower engines. He has three choices to decide from: Seymour, Indiana; Daventry, England; and Pune, India. The Community Education Coalition (CEC) in Columbus has had success in improving the city's schools to make the area more competitive in attracting and retaining highly educated employees to this small Midwestern city. The CEC is planning an expansion into Seymour with Cummins' help. Will the CEC be able to improve the school system in Seymour enough to make it a viable choice for the new high horsepower engine line?

  Keywords: manufacturing; education; competitiveness; Manufacturing Industry; United States;

  Citation:

  Bower, Joseph L., and Michael Norris. "Cummins, Inc.: Building a Home Community for a Global Company." Harvard Business School Case 313-024, March 2013.

  CiteView Details

  Related

• Course Overview Note | 2013 (Revised from original 2013 version)

  The Entrepreneurial Manager: Course Overview, 2013 Winter Term

  Richard G. Hamermesh, Richard G. Hamermesh and Thomas Eisenmann

  Course overview of The Entrepreneurial Manager.

  Keywords: Entrepreneurship; Management; Business Education;

  Citation:

  Hamermesh, Richard G., and Thomas Eisenmann. "The Entrepreneurial Manager: Course Overview, 2013 Winter Term." Harvard Business School Course Overview Note 813-155, January 2013. (Revised from original January 2013 version.)

  CiteView DetailsPurchase

  Related

• Case | HBS Case Collection | 2013 (Revised from original 2012 version)

  Companion Diagnostics: Uncertainties for Approval and Reimbursement

  Richard G. Hamermesh, Norman C. Selby and Phillip Andrews

  The FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine. The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory practices at the agency. Beyond the regulatory questions, many considered the reimbursement system archaic, dispersed, unpredictable, and unnecessarily time consuming. Many questioned whether the traditional models of reimbursement were relevant in the era of personalized medicine, and who should be covering the cost of tests needed to identify the sometimes small number of patients who could benefit from expensive targeted drugs. This case focuses on the array of possibilities and the ambiguity surrounding these regulatory and reimbursement issues.

  Keywords: models of reimbursement; personalized medicine; regulation; healthcare reform; Health Care and Treatment; Health Industry; United States;

  Citation:

  Hamermesh, Richard G., Norman C. Selby, and Phillip Andrews. "Companion Diagnostics: Uncertainties for Approval and Reimbursement." Harvard Business School Case 813-037, January 2013. (Revised from original November 2012 version.)

  CiteView DetailsPurchase

  Related